The discrepancies across these studies likely stem from the many variables in study designs, including those focused on the TBI itself (i.e., TBI model, injury severity, injury frequency), as well as in modeling tauopathy (wildtype human tau vs. mutant tau, overexpression vs. endogenous levels, and ratios of different tau isoforms). The gene discussed is MAPT; the disease is tauopathy.